|Bid||132.80 x 400|
|Ask||138.62 x 100|
|Day's Range||133.43 - 137.30|
|52 Week Range||73.41 - 153.15|
|PE Ratio (TTM)||-239.20|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Shares of Seattle Genetics (SGEN) are moving lower today, falling more than 9% after the drug maker’s experimental lymphoma drug failed to impress. The data from the late-stage study testing Adcetris, co-developed with Japan's Takeda Pharmaceutical, helped blood cancer patients live longer without worsening their conditions, meeting its endpoint. Altogether, lots of uncertainty whether these data could support a robust commercial adoption.
Biotech shares have surged during the week of June 19.
Categories: ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Incyte Corp.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bullish Closing Price above/below 200 Day Moving Average Bullish 50 ... Read more (Read more...)